• Bingxin Xie, Bao Wu, Mingzhang Zhao, Yili Liu, Guolei Xu, and Qiao Li.
• Department of Cardiovascular Medicine, Southern Branch of Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
• Medicine (Baltimore). 2022 Dec 23; 101 (51): e32283e32283.

BackgroundThere is no evidence-based data to confirm the efficacy of Yiqi Huoxue Yangxin Decoction combined with Western medicine in patients with coronary heart disease (CHD). Therefore, in order to provide new medical evidence for clinical treatment, we used this protocol to conduct a systematic review and meta-analysis on the effectiveness and safety of Yiqi Huoxue Yangxin Decoction combined with Western medicine in patients with CHD.MethodsThe systematic review protocol is registered in PROSPERO under registration number CRD42022372800. The systematic literature review will follow PRISMA guidelines (Preferred Reporting Items for Systematic Reviews and Meta-Analyses). The following search terms will be used in PUBMED, Scopus, EMBASE, Cochrane Library, CNKI, Wan Fang, and VIP on December 1, 2022. Two independent authors extract the following descriptive raw information from selected studies: study characteristics such as authors, year of publication, study design; patient demographic information such as number of patients, mean age, body mass index, and sex ratio. The primary outcome of interest is symptom scores. Secondary outcomes include ECG effective rate, improvement of blood lipid index, and adverse events. The Cochrane Bias Risk Tool is used independently by 2 reviewers to assess the risk of bias in included randomized controlled trials. The quality of retrospective studies will be assessed using the Newcastle-Ottawa scale.ConclusionsThe results of our review will be reported strictly following the PRISMA criteria and the review will add to the existing literature by showing compelling evidence and improved guidance in clinic settings.Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

10 keywords...

hide…